hALB/hFCRN

Nomenclature

C57BL/6Smoc-Albtm3(hALB)Fcgrttm2(hFCGRT)/Smoc

Cat. NO.

NM-HU-200278

Strain State

Repository Live

Export PDF

Model Description

hALB(NM-HU-200003)was crossed with hFcRn(NM-HU-190070)to generate hALB/hFCRN mice

Validation Data


image.png

Fig.1 Detection of hALB (A) and mALB (B) expression in serum by ELISA (n=3). 

Abbr. HO, homozygous; WT, wild type.image.png

Fig.2 Expression characterization of hFCRN in hALB/hFCRN dKI mice by Western blot. (Arrow indicates expected molecular weight and asterisk indicates a nonspecific band)  

image.png

Fig.3 In vivo PK profiles of TAA scfv-anti HSA VHH in hALB/hFCRN mice (female, 10-12weeks, n=3 mice/timepoint).

(In cooperation with the third party).

image.png

Fig.4 Blood concentration curves of test articles in C57BL/6 and hFcRn/hALB dKI mice. (In cooperation with the third party) 

image.png

Table 1 Noncompartmental Analysis (NAC) results of test articles in hFcRn/hALB dKI mice. (In cooperation with the third party) 



image.png

Fig.5 Fitting curves of blood concentration in C57BL/6 and hFcRn/hALB dKI mice. (In cooperation with the third party) 

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more